Connect with us

Technology

Lindus Health Rolls Out “All-in-One Infectious Disease CRO” Bespoke to Clinical Trials for Infectious Disease Interventions

Published

2 years ago

on

NEW YORK, Nov. 19, 2024 /PRNewswire/ — Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, has introduced their versatile contract research organization (CRO), site, and technology offering tailor-made to the execution of infectious disease trials.

Clinical development of infectious disease treatments and diagnostics must account for complexities such as diverse and evolving pathogens, seasonality and localization of study sites, and enrollment at the appropriate time during infection. Having enrolled over 5,000 patients in infectious disease studies across the US, EU, and UK, Lindus Health is well-equipped to handle the unique challenges within this therapeutic area.

Lindus Health’s latest solution for the infectious disease market segment leverages their full-spectrum CRO and site services, rooted in deep expertise in running infectious disease clinical trials. They are able to recruit diverse study populations at twice the speed of traditional CROs through their expansive recruitment capabilities, including targeted digital outreach campaigns, healthcare and community organization collaborations, and electronic health record (EHR) screening from a repository of over 30 million patients.

“Infectious disease studies require swift and adaptable approaches for execution and recruitment to keep pace with evolving pathogens and public health needs,” said Meri Beckwith, co-founder of Lindus Health. “Therefore speed of execution and access to real-time data are essential, while ensuring enrollment of diverse and representative patient populations.”

The “All-in-One Infectious Disease CRO” offers a comprehensive suite of resources and services to support infectious disease research, including:

Full-service CRO solutions: From protocol writing and study startup to close-out and data delivery, Lindus Health’s clinical operations team oversees all aspects of infectious disease trials, handling all project management and administrative responsibilities.Innovative recruitment strategies: With partnerships across primary care, urgent care, and local community groups as well as EHR screening and direct-to-patient marketing, Lindus employs advanced methods to quickly recruit diverse patient populations in infectious disease studies.Adaptable eClinical software: Citrus™, Lindus’ proprietary clinical research platform custom-built for each trial, stitches together essential tools such as clinical trial management software (CTMS), electronic data capture (EDC), telehealth, and eConsent, providing a true all-in-one solution for cohesive study management.Regulatory and industry insights: Lindus offers expertise on regulatory standards and emerging developments within infectious disease research.Comprehensive site services: Lindus’ site operations team collaborates closely with principal investigators and research staff to execute women’s health trials across single-site, multi-site, hybrid, and fully virtual environments.

“The escalating prevalence and rapid evolution of infectious pathogens present significant challenges to developing interventions to treat, detect, and protect against infectious diseases,” said Dr. Robert Langer, Institute Professor at Massachusetts Institute of Technology and Scientific Advisor to Lindus Health. “With their innovative, agile approaches to trial execution, I believe Lindus Health is well-equipped to quickly adapt and overcome these challenges as they arise.”

Lindus Health is devoted to supporting infectious disease sponsors in bringing groundbreaking treatments and diagnostics to patients and healthcare providers by streamlining all stages of the clinical trial workstream.

To learn more about the “All-in-One Infectious Disease CRO” offering, click here.

About Lindus Health

Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved  through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 30 million Electronic Health Records.

Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint by handling the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.

To date, Lindus Health has delivered clinical trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.

Lindus Health Media Contact:
Jodi Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lindus-health-rolls-out-all-in-one-infectious-disease-cro-bespoke-to-clinical-trials-for-infectious-disease-interventions-302309386.html

SOURCE Lindus Health

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Mastech Digital to Announce Second Quarter 2026 Financial Results; Participate in Upcoming Investor Conference

Published

32 minutes ago

on

July 24, 2026

By

PITTSBURGH, July 24, 2026 /PRNewswire/ — Mastech Digital, Inc. (NYSE American: MHH) (“Mastech Digital”), a leading provider of Digital Transformation IT Services, today announced the date for the release of its financial results for the second quarter ended June 30, 2026, and its participation in an upcoming investor conference.

Second Quarter 2026 Earnings:

Mastech Digital will report its financial results for the second quarter 2026 before the market opens on Thursday, August 6, 2026. Management will host a live conference call and webcast at 9:00 a.m. Eastern Time on that day to discuss the Company’s financial performance and operating results.  The conference call will be hosted by Nirav Patel, President and CEO, and Kannan Sugantharaman, Chief Financial and Operations Officer.

Those wishing to participate via webcast should access the call through Mastech Digital’s Investor Relations website at https://investors.mastechdigital.com. Those wishing to participate via telephone may dial in at 1-800-715-9871 (USA) or 1-646-307-1963 (International) with the passcode 7506988. The replay will be available via webcast through Mastech Digital’s Investor Relations website.

Upcoming Investor Conference:

Mr. Sugantharaman will host a fireside chat at the Sidoti Micro-Cap Investor Conference on Wednesday, August 19, 2026, at 9:15 a.m. Eastern Time.

Mastech Digital management is scheduled to host virtual one-on-one and small group meetings with investors during the conference on August 19-20, 2026. Investors interested in arranging a meeting should contact their Sidoti representative or reach out to the Mastech Digital investor relations team at investors@mastechdigital.com.

About Mastech Digital, Inc.

Mastech Digital (NYSE American: MHH) is a leading provider of Digital Transformation IT Services. The Company offers Data Management, Analytics & AI Solutions, and IT Staffing Services with a digital-first approach. A minority-owned enterprise, Mastech Digital is headquartered in Pittsburgh, PA, with offices across the U.S., Canada, Europe, and India. Visit us at www.mastechdigital.com.

Investor Relations Contact:
investors@mastechdigital.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mastech-digital-to-announce-second-quarter-2026-financial-results-participate-in-upcoming-investor-conference-302834421.html

SOURCE Mastech Digital, Inc.

Continue Reading

Technology

SOLAI Limited Announces Extraordinary General Meeting

Published

32 minutes ago

on

July 24, 2026

By

AKRON, Ohio, July 24, 2026 /PRNewswire/ — SOLAI Limited (NYSE: SLAI) (“SOLAI” or the “Company”) (previously known as “BIT Mining Limited”), a technology-driven personal AI and digital infrastructure provider, today announced that it will hold its extraordinary general meeting of shareholders at 428 South Seiberling Street, Akron, Ohio, US on August 14, 2026 at 10:00 a.m., New York time.

Holders of record of ordinary shares and preference shares of the Company at the close of business on July 20, 2026, New York time (the “Record Date”) are entitled to receive notice of, and to attend and vote at, the extraordinary general meeting or any adjournment thereof. Holders of the Company’s American Depositary Shares (“ADSs”) who wish to exercise their voting rights for the underlying ordinary shares must act through the depositary of the Company’s ADS program, Deutsche Bank Trust Company Americas.

The notice of the extraordinary general meeting, which sets forth the resolutions to be submitted to shareholder approval at the extraordinary general meeting is available on the Investor Relations section of the Company’s website at https://ir.solai.com. 

About SOLAI Limited

SOLAI Limited (previously known as “BIT Mining Limited”) (NYSE: SLAI) (previously traded under “BTCM”) is a technology-driven personal AI and digital infrastructure provider. Building upon its historical legacy in digital asset mining and blockchain network operations, the Company is leveraging extensive experience in large-scale hardware deployment, data center operations, and high-performance computing to build the foundational infrastructure for personal AI computing and digital asset ecosystems globally.

For more information:

SOLAI Limited
ir@solai.com
ir.solai.com
www.solai.com 

Christensen Advisory
Jason Ng
Tel: +852-2117-0861
Email: solai@christensencomms.com 

 

View original content:https://www.prnewswire.com/news-releases/solai-limited-announces-extraordinary-general-meeting-302834034.html

SOURCE SOLAI Limited

Continue Reading

Technology

/U P D A T E — TrendAI/

Published

2 hours ago

on

July 24, 2026

By

This release has been updated to include new information provided by TrendAI. The complete, corrected release follows, with additional details at the end:

TrendAI™ Adopts Claude Opus 5 to Advance Vulnerability Prioritization and Virtual Patching

As a participant in Anthropic’s Cyber Verification Program, TrendAI applies frontier reasoning to convert vulnerability intelligence into faster protection across hybrid environments

DALLAS, July 24, 2026 /PRNewswire/ — TrendAI™, the enterprise AI security leader from Trend Micro Incorporated (TYO: 4704; TSE: 4704), today announced it is adopting Claude Opus 5, Anthropic’s latest and most capable Opus model, to help security teams convert vulnerability intelligence into immediate protection, from prioritization to virtual patching. The move builds on TrendAI’s collaboration with Anthropic on Claude Opus 4.8, extending the same defensive focus to a model that delivers step-change gains in advanced reasoning, agentic workflows, and long-horizon analysis. As AI makes finding vulnerabilities easier than ever, the harder problem becomes protecting organizations faster than software can be permanently patched, and that is where TrendAI is putting Opus 5 to work.

As a participant in Anthropic’s Cyber Verification Program, which credentials organizations for the defensive use of frontier AI models, TrendAI is positioned to apply Claude Opus 5 to defensive security as access becomes available. The model is Zero Data Retention compatible, supporting TrendAI’s governance and data-protection requirements as it scales AI across security operations.

The work extends to TrendAI Threat Research, where frontier AI models are combined with our proprietary frontier intelligence engine and human expertise to generate pre-disclosure intelligence. Those insights power TrendAI Vision One™, delivering stronger detection, deeper forensic insights, and proactive protection through virtual patching.

Rachel Jin, Chief Platform and Business Officer, Head of TrendAI™:
“With Claude Opus 5, TrendAI can move from vulnerability intelligence to action faster than ever, prioritizing what matters most by exploitability and business impact. Finding the vulnerability was always the hard part. Now the challenge is protecting organizations faster than software can be permanently patched, and frontier reasoning is what changes that equation, extending all the way to virtual patching that protects customers before a vendor fix ships. This is what it means to secure the AI age, fearlessly.”

These capabilities support TrendAI Vision One™ in helping security analysts, AppSec teams, and SOC teams prioritize exposure, map attack paths, and accelerate mitigation, including virtual patching, across hybrid environments, moving vulnerability management from a static scanning process into a faster, context-aware risk mitigation workflow.

About TrendAI™
TrendAI™, the global AI security leader and enterprise business unit of Trend Micro, empowers organizations with full AI visibility and consolidated security that inspires confidence, drives innovation, and eliminates risk. Trusted by the largest enterprises and governments across 185 countries, TrendAI™ secures the entire organization, from identities, to infrastructure, to data. Global Fortune 500 companies rely on TrendAI™ to cut risk and stop threats up to three months earlier, powered by world-leading threat and attack intelligence. Through deep ecosystem partnerships with market leaders like NVIDIA, Anthropic, AWS, Google, and Microsoft, TrendAI™ empowers your organization to securely drive forward at the speed of AI. AI Fearlessly. Learn more: trendaisecurity.com

About Anthropic
Anthropic is an AI safety and research company dedicated to building reliable, interpretable, and steerable AI systems. Its Claude family of models, including Claude Opus 5, enables advanced capabilities across a wide range of applications, including code understanding and security analysis.

Update: The latest version of this release includes additional statements from TrendAI related to the original announcement.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trendai-adopts-claude-opus-5-to-advance-vulnerability-prioritization-assessment-and-virtual-patching-302834362.html

SOURCE TrendAI

Continue Reading

Trending